Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Preferred Stock and Equity Offerings (Details Narrative)

Preferred Stock and Equity Offerings (Details Narrative) - USD ($)														1 Months Ended			3 Months Ended	12 Months Ended
	Oct. 12, 2017	Jul. 31, 2017	Jul. 07, 2017	Jul. 05, 2017	Jun. 21, 2017	Jun. 21, 2017	Jun. 16, 2017	Apr. 18, 2017	Mar. 22, 2017	Mar. 22, 2017	Feb. 08, 2017	Jan. 25, 2017	Jan. 06, 2017	Apr. 18, 2017	Feb. 28, 2017	Dec. 31, 2016	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Oct. 31, 2014
Preferred stock, shares authorized																5,000,000		5,000,000	5,000,000
Net proceeds from equity offerings		$ 960,000																$ 29,900,000
Number of common stock issued, shares						9,900,000
Proceeds from issuance of common stock																		23,081,000	$ 1,707,000
Warrants to purchase shares of common stock		875,000
Proceeds from issuance or sale of equity																		29,900,000
Fair value of warrants issued																	$ 200,000	141,000
Option to purchase overallotment option, percentage							4.00%
Warrant term				3 years
Debt conversion, converted instrument, amount																		11,643,000
Loss on conversion of convertible debt																		$ 4,300,000
Underwriters' overallotment option to purchase common stock		875,000					1,875,000
Debt instrument beneficial percentage, description																		The company offered to each purchaser whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% of our outstanding common stock. Subject to limited exceptions, a holder of pre-funded warrants could not have the right to exercise any portion of its pre-funded warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of common stock outstanding immediately after giving effect to such exercise. Each pre-funded warrant was exercisable for one share of our common stock.
Warrant exercised																		1,700,000
Warrant exercise price	$ 1.25			$ 1.25
Underwriters purchase common stock, value		$ 960,000
Proceeds from warrants																		$ 193,000
Warrant expiring date				Aug. 31, 2020
Warrants exercisable into common stock				150,000
Other (expense) income, net																		(2,128,000)	14,000
Gross proceeds from warrant exercise																		2,100,000
Underwriter Discount [Member]
Underwriters purchase common stock, value		72,000
Proceeds from warrants		$ 882,000
RedPath Note [Member]
Repayments of debt																$ 1,330,000
Debt instrument principal amount																9,340,000			9,340,000	$ 10,700,000
RedPath Note [Member] \| Senior Secured Non-Convertible Note [Member]
Debt instrument principal amount									$ 3,550,000	$ 3,550,000								$ 3,550,000
Debt conversion, converted instrument, amount								$ 3,550,000
Debt conversion, converted instrument, shares issued								3,795,429						3,795,429
RedPath Note [Member] \| Investor [Member]
Fair value of warrants issued										500,000
Acquisition of debt										$ 8,870,000
RedPath Note [Member] \| Investor [Member] \| Senior Secured Non-Convertible Note [Member]
Debt instrument principal amount								$ 3,550,000						$ 3,550,000
RedPath Note [Member] \| RedPath Integrated Pathology, Inc [Member]
Debt instrument principal amount																9,340,000			9,340,000
Senior Secured Convertible Note [Member]
Debt instrument principal amount																5,320,000			5,320,000
Senior Secured Non-Convertible Note [Member]
Debt instrument principal amount																$ 3,550,000			$ 3,550,000
Termination Agreement [Member] \| RedPath Equityholder Representative [Member]
Warrants to purchase shares of common stock									100,000	100,000
Common stock purchase price per share									$ 4.69	$ 4.69
Fair value of warrants issued									$ 190,000
Warrant term									5 years
Employee Severance [Member]
Payments for restructuring															$ 1,000,000
Private Placement [Member]
Warrant exercise price	1.80
First Registered Direct Offering [Member]
Number of common stock issued, shares													630,000
Common stock price, per share													$ 6.81
Proceeds from issuance of common stock													$ 4,300,000
Second Registered Direct Offering [Member]
Number of common stock issued, shares												855,000
Fair value of warrants issued												$ 1,670,000
Second Registered Direct Offering [Member] \| Employee Severance [Member]
Payments for restructuring												$ 1,000,000
Second Registered Direct Offering [Member] \| Private Placement [Member]
Warrants to purchase shares of common stock												855,000
Common stock purchase price per share												$ 4.69
Proceeds from issuance or sale of equity												$ 4,000,000
Confidentially Marketed Public Offering (CMPO) [Member]
Number of common stock issued, shares											1,200,000
Common stock price, per share											$ 3.00
Proceeds from issuance or sale of equity											$ 3,900,000
Option to purchase overallotment option, percentage											9.00%
Common Stock [Member]
Number of common stock issued, shares																		34,000
Warrants to purchase shares of common stock							9,900,000
Base Warrants [Member]
Net proceeds from equity offerings						$ 13,700,000
Number of common stock issued, shares						12,500,000
Warrants to purchase shares of common stock							12,500,000
Common stock purchase price per share							$ 1.25
Fair value of warrants issued						$ 5,300,000
Common stock effective purchase price							$ 1.10
Underwriters' overallotment option to purchase common stock							1,875,000
Underwriter Warrants[Member]
Number of common stock issued, shares					575,000
Warrants to purchase shares of common stock							2,600,000
Common stock purchase price per share							$ 0.01
Warrant exercise price																		$ 1.32
Base Warrant And Prefunded Warrants [Member]
Common stock effective purchase price							$ 1.09
Oveallotment Warrants [Member]
Warrants to purchase shares of common stock					1,875,000	1,875,000
Common stock purchase price per share					$ 0.01	$ 0.01
Pre-Funded Warrants [Member]
Net proceeds from equity offerings						$ 12,300,000
Number of common stock issued, shares						2,600,000
Warrants to purchase shares of common stock			2,600,000				2,600,000
Common stock purchase price per share							$ 1.09
Fair value of warrants issued			$ 2,300,000
Underwriting discount rate							7.50%
Offering and over-allotment and reasonable out-of-pocket expenses							$ 100,000
Warrant exercised			2,600,000
Warrant exercise price			$ 0.01				$ 1.09											$ 0.01
Proceeds from warrants			$ 26,000,000
Overallotment Warrants [Member]
Number of common stock issued, shares					1,875,000
Fair value of warrants issued					$ 800,000
4 Million Base Warrants [Member]
Common stock purchase price per share	$ 1.25
Proceeds from warrants	$ 5,000,000
Other (expense) income, net	$ 2,000,000
4 Million Base Warrants [Member] \| Private Placement [Member]
Warrants to purchase shares of common stock	3,200,000
Warrant exercise price	$ 1.80